Change of treatment from cyclosporin to mycophenolate mofetil in severe psoriasis
β Scribed by S.C. Davison; R. Morris-Jones; A.V. Powles; L. Fry
- Publisher
- John Wiley and Sons
- Year
- 2000
- Tongue
- English
- Weight
- 192 KB
- Volume
- 143
- Category
- Article
- ISSN
- 0007-0963
No coin nor oath required. For personal study only.
β¦ Synopsis
Eight patients whose severe psoriasis was treated with long-term cyclosporin (range 2-11 years; mean 7.6 years) were changed to mycophenolate mofetil (MMF), because of nephrotoxicity in seven and hypertension and lack of efficacy in one. In five patients psoriasis control significantly deteriorated and in three patients disease control deteriorated slightly in periods ranging from 2 to 32 weeks. Renal function improved in all six patients with cyclosporin-induced nephrotoxicity treated with MMF for more than 2 weeks. From this data it would appear that MMF is not as effective as cyclosporin in controlling severe psoriasis. However, MMF did offer reasonable disease control in three of eight patients and allowed renal function to improve, and so may have a place in the treatment of some patients unable to take cyclosporin because of renal toxicity.
π SIMILAR VOLUMES
This study investigates the tolerability, safety and efficacy of abrupt or stepwise switching from donepezil to memantine treatment in patients with moderate-to-severe Alzheimer's disease (AD). Outpatients (Table 1), !50 years, with dementia of the Alzheimer's type (DSM-IV-TR), MMSE 18 and receiving
## Abstract We report the first largeβscale doubleβblind, randomly assigned study to compare two active dopaminergic therapies for Restless Legs Syndrome (RLS), the dopamine agonist cabergoline (CAB) and levodopa/benserazide (levodopa). Patients with idiopathic RLS were treated with fixed daily dos